PFE · 10-Q · 2026Q2 · Full report

Manufacturing and Capacity

PFIZER INC · 2026-08-04 · Importance 39 · Surprise 50 · No source text

Pfizer CentreOne second-quarter 2026 revenue increased 5% operationally, driven by higher manufacturing of third-party products under manufacturing and supply agreements and higher active pharmaceutical ingredient sales. The company announced a further manufacturing-optimization phase focused on network-structure changes, product-portfolio enhancements and operational efficiencies. The phase is expected to produce approximately $1.5 billion of additional savings through 2029, with some benefits beginning in 2027. Pfizer stated that its global manufacturing sites continued to operate at or near normal levels during the first six months of 2026.

Key facts

• With the additional Manufacturing Optimization Program savings, Pfizer now expects total net cost savings of approximately $3.0 billion from the program through 2029. source
• Manufacturing Optimization Program next phase announced in third quarter of 2026 expected to deliver additional anticipated savings of approximately $1.5 billion through 2029, with one-time costs to achieve the savings expected to be approximately $4.0 billion (approximately 60% non-cash) incurred through 2029. source
• Pfizer discloses it expects to continue investing in U.S. manufacturing as part of its forward-looking information and voluntary agreements with the U.S. Government designed to lower drug costs and include certain Pfizer products on the TrumpRx.gov platform. source

Impact estimates